Inovio Pharmaceuticals Inc
NASDAQ:INO

Watchlist Manager
Inovio Pharmaceuticals Inc Logo
Inovio Pharmaceuticals Inc
NASDAQ:INO
Watchlist
Price: 4.07 USD 0.25% Market Closed
Market Cap: 105.7m USD
Have any thoughts about
Inovio Pharmaceuticals Inc?
Write Note

Inovio Pharmaceuticals Inc
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Inovio Pharmaceuticals Inc
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
Inovio Pharmaceuticals Inc
NASDAQ:INO
Other Equity
-$623.5k
CAGR 3-Years
-34%
CAGR 5-Years
N/A
CAGR 10-Years
-19%
Abbvie Inc
NYSE:ABBV
Other Equity
-$2.3B
CAGR 3-Years
10%
CAGR 5-Years
2%
CAGR 10-Years
-10%
Gilead Sciences Inc
NASDAQ:GILD
Other Equity
$18.4B
CAGR 3-Years
526%
CAGR 5-Years
175%
CAGR 10-Years
61%
Amgen Inc
NASDAQ:AMGN
Other Equity
-$336m
CAGR 3-Years
25%
CAGR 5-Years
6%
CAGR 10-Years
-12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Equity
-$22.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Equity
$60.2m
CAGR 3-Years
82%
CAGR 5-Years
29%
CAGR 10-Years
8%
No Stocks Found

Inovio Pharmaceuticals Inc
Glance View

Market Cap
106m USD
Industry
Biotechnology

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in San Diego, California and currently employs 317 full-time employees. The firm is focused on bringing to market designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus (HPV). Its DNA medicines pipeline consists of three types of product candidates, namely prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies (dMAbs and dBTAs), which utilizes the two components of INOVIO's integrated platform, SynCon and CELLECTRA. The firm's SynCon technology creates optimized plasmids. INOVIO's CELLECTRA smart delivery devices facilitate uptake of its DNA medicines into the cell. Its SynCon DNA medicines are designed to generate antigen-specific antibody and T cell responses.

INO Intrinsic Value
5.99 USD
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Inovio Pharmaceuticals Inc's Other Equity?
Other Equity
-623.5k USD

Based on the financial report for Sep 30, 2024, Inovio Pharmaceuticals Inc's Other Equity amounts to -623.5k USD.

What is Inovio Pharmaceuticals Inc's Other Equity growth rate?
Other Equity CAGR 10Y
-19%

Over the last year, the Other Equity growth was 17%. The average annual Other Equity growth rates for Inovio Pharmaceuticals Inc have been -34% over the past three years , and -19% over the past ten years .

Back to Top